Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn't Happening. - Barron's

Biotech stocks are off almost 60% from their February 2021 peak, and the top 20 biopharma companies together have almost $300 billion of cash.

With biotech stocks off nearly 60% from their February 2021 peak, and big pharma firms flush with cash, why havent there been more acquisitions this year? Its a healthcare market paradox.A note Frida… [+3242 chars]

full article...